4 reports of this reaction
4.5% of all POTASSIUM CHLORIDE FOR ORAL SOLUTION reports
#5 most reported adverse reaction
RESPIRATORY ARREST is the #5 most commonly reported adverse reaction for POTASSIUM CHLORIDE FOR ORAL SOLUTION, manufactured by Ajenat Pharmaceuticals LLC. There are 4 FDA adverse event reports linking POTASSIUM CHLORIDE FOR ORAL SOLUTION to RESPIRATORY ARREST. This represents approximately 4.5% of all 88 adverse event reports for this drug.
Patients taking POTASSIUM CHLORIDE FOR ORAL SOLUTION who experience respiratory arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY ARREST is moderately reported among POTASSIUM CHLORIDE FOR ORAL SOLUTION users, representing a notable but not dominant share of adverse events.
In addition to respiratory arrest, the following adverse reactions have been reported for POTASSIUM CHLORIDE FOR ORAL SOLUTION:
The following drugs have also been linked to respiratory arrest in FDA adverse event reports:
RESPIRATORY ARREST has been reported as an adverse event in 4 FDA reports for POTASSIUM CHLORIDE FOR ORAL SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY ARREST accounts for approximately 4.5% of all adverse event reports for POTASSIUM CHLORIDE FOR ORAL SOLUTION, making it a notable side effect.
If you experience respiratory arrest while taking POTASSIUM CHLORIDE FOR ORAL SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.